OverviewSuggest Edit

DAXOR is a biotechnology company that provides original medical equipment for medical personnel. The Company manufactures the BVA-100 Blood Volume Analyzer, the first machine approved by the FDA that provides rapid direct measurement of a patient’s blood volume. 

TypePublic
Founded1970
HQNew York, US
Websitedaxor.com

Latest Updates

Employees (est.) (Jun 2017)37
Revenue (FY, 2011)$1.4 M
Share Price (Nov 2020)$13.6
Cybersecurity ratingAMore

Key People/Management at DAXOR

Michael R. Feldschuh

Michael R. Feldschuh

Director
Michael Feldschuh

Michael Feldschuh

President and Chief Executive
Jonathan Feldschuh

Jonathan Feldschuh

Chief Scientific Officer
James A. Lombard

James A. Lombard

Director
Robert J. Michel

Robert J. Michel

CFO
Soren Thompson

Soren Thompson

Vice President Business Development
Show more

DAXOR Office Locations

DAXOR has an office in New York
New York, US (HQ)
350 5th Ave #4740
Show all (1)

DAXOR Financials and Metrics

DAXOR Revenue

DAXOR's revenue was reported to be $1.45 m in FY, 2011
USD

Revenue (FY, 2011)

1.4m

Gross profit (FY, 2011)

793.8k

Gross profit margin (FY, 2011), %

54.9%

Net income (FY, 2011)

(7.2m)

EBIT (FY, 2011)

(5.8m)

Market capitalization (26-Nov-2020)

52.9m

Closing stock price (26-Nov-2020)

13.6

Cash (31-Dec-2011)

59.6k

EV

52.9m
DAXOR's current market capitalization is $52.9 m.
Annual
USDFY, 2011

Revenue

1.4m

Cost of goods sold

652.5k

Gross profit

793.8k

Gross profit Margin, %

55%
Quarterly
USDQ2, 2011Q3, 2011

Revenue

358.1k340.9k

Cost of goods sold

160.7k149.4k

Gross profit

197.4k191.5k

Gross profit Margin, %

55%56%
Annual
USDFY, 2011

Cash

59.6k

Accounts Receivable

219.7k

Prepaid Expenses

209.3k

Inventories

301.5k
Quarterly
USDQ2, 2011Q3, 2011

Cash

111.8k29.7k

Accounts Receivable

193.5k189.6k

Prepaid Expenses

184.3k338.3k

Inventories

357.3k313.5k
Annual
USDFY, 2011

Net Income

(7.2m)

Depreciation and Amortization

290.8k

Inventories

(62.1k)

Accounts Payable

88.6k
Quarterly
USDQ2, 2011Q3, 2011

Net Income

(1.5m)(5.7m)

Depreciation and Amortization

147.0k219.5k

Inventories

(6.3k)(50.1k)

Accounts Payable

626.1k534.6k
USDQ2, 2011

Financial Leverage

2.1 x
Show all financial metrics

DAXOR Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

DAXOR Online and Social Media Presence

Embed Graph

DAXOR News and Updates

New Research Demonstrates Daxor BVA-100® Blood Test Provides “Extremely Cost-Effective” Improvement in Patient Life Span at the Heart Failure Society of America Annual Scientific Meeting 2020

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces compelling new data demonstrating further beneficial use of Daxor’s blood v…

Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020 on the Value of BVA-100®

NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be exhibiting and showcasing new data at the Heart Failur…

Daxor to Present at the Inaugural Sepsis Alliance Summit

NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be participating in the inaugural Sepsis Alliance Summit.…

Daxor Corporation to Present at the LD 500 Virtual Investor Conference

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that it will be presenting at the LD 500 Virtual Investor Conference schedu…

Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for U.S. Air Force Needs

NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Air Force (USAF) has awarded Daxor a contract to define spec…

Daxor Corporation Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market

NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreem…
Show more

DAXOR Blogs

Third Hospital Joins Multicenter Covid-19 BVA-100® Blood Test Study

NEW YORK, November 19, 2020 — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hosp…

Daxor Announces Cooperative Research & Development Agreement with the Uniformed Services University of the Health Sciences

NEW YORK, August 4, 2020 — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with The U…
Show more

DAXOR Frequently Asked Questions

  • When was DAXOR founded?

    DAXOR was founded in 1970.

  • Who are DAXOR key executives?

    DAXOR's key executives are Michael R. Feldschuh, Michael Feldschuh and Jonathan Feldschuh.

  • How many employees does DAXOR have?

    DAXOR has 37 employees.

  • What is DAXOR revenue?

    Latest DAXOR annual revenue is $1.4 m.

  • What is DAXOR revenue per employee?

    Latest DAXOR revenue per employee is $39.1 k.

  • Who are DAXOR competitors?

    Competitors of DAXOR include Humasis, Zepto Life Technology and ArcDia.

  • Where is DAXOR headquarters?

    DAXOR headquarters is located at 350 5th Ave #4740, New York.

  • Where are DAXOR offices?

    DAXOR has an office in New York.

  • How many offices does DAXOR have?

    DAXOR has 1 office.